Asthma

Sepracor presents data for two forms of Xopenex (levalbuterol)

Published in Hospital Business Week, November 26th, 2006

Sepracor Inc. (SEPR) announced the presentation of posters of clinical data from studies of Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol and Xopenex (levalbuterol HCl) Inhalation Solution at CHEST 2006, the annual meeting of the American College of Chest Physicians (ACCP), in Salt Lake City.

Results of a randomized, prospective, open-label, multi-center study assessing clinical outcomes based on the number of nebulizations throughout the duration of the hospital stay and cost-effectiveness in hospitalized patients administered either Xopenex Inhalation Solution (n=241) or racemic albuterol (n=238) by nebulization were presented. Upon admission to the hospital,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hospital Business Week

Source: Hospital Business Week (2006-11-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry